Table 5.
Leukocyte adhesion and extravasation.
| Ligand | Site on CR3 | Site on ligand | Function | |
|---|---|---|---|---|
| ICAM-1 (CD54) | αMI, DXSXS in β2, not competing with fibrinogen | 3. Ig domain | Leukodiapedesis – expression only in inflammatory sites | (185–189) |
| ICAM-2 (CD102) | αMI, not competing with iC3b, fibrinogen and FX | 1. Ig domain | T cell aggregation, NK cell migration and cytotoxicity | (190, 191) |
| ICAM-4 | Divalent cation dependent | Ig domains D1 and D2 | – | (192) |
| JAM-C (junctional adhesion molecule) |
αMI, competing with fibrinogen | – | Platelet-neutrophil interaction, transepithelial migration | (193, 194) |
| CD147 (Basigin) | – | – | – | (195) |
| RAGE (AGER) | αMI, competing with fibrinogen and HMWK | – | Neutrophil extravasation into peritoneum | (196) |
| Thy-1 (CD90) | αMI, not competing with ICAM-1 | – | Neutrophil adhesion to endothelial cells, migration, accumulation in skin lesions | (197, 198) |
| SIRPα (signal regulatory protein α) |
αMI | Ig1-2-3 ectodomain | Macrophage fusion, anti-phagocytosis signal | (199) |
| CD40L | αMI, distinct of fibrinogen | Distinct from CD40 and GPIIb/IIIa binding site | leukocyte recruitment in atherosclerosis | (200) |
| Myeloperoxidase | – | – | – | (201) |
| Azurocidin and Elastase | – | Catalytic domain | – | (202) |
| Pro-MMP-2, Pro-MMP-9 | αMI | Catalytic domain | Suggested to be involved in neutrophil migration | (203, 204) |
| Pleiotrophin | αMI | Thrombospondin type-1 repeat domains | Macrophage migration, MAP kinase activation, phosphorylation of Erk1/2 | (205) |
| Dynorphin A | αMI | Enhanced phagocytosis | (206) | |
| DC-SIGN | LeX on CD11b, binds only to CR3 on PMNs | CRD | DC maturation, cytokine production | (32) |